Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors.
Da Hyun KangChaeuk ChungPureum SunDa Hye LeeSong I LeeDong Il ParkJeong Suk KohYoonjoo KimHyon Seung YiJeong Eun LeePublished in: Cancer immunology, immunotherapy : CII (2021)
Circulating Treg cells represent a promising potential dynamic biomarker to predict efficacy and differentiate atypical responses, including pseudoprogression and hyperprogression, after immunotherapy in patients with NSCLC.